Clinical Trial Update: Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Rituximab, Venetoclax, and Bortezomib for relapsed or refractory diffuse large B-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc and Bcl2 or Bcl6 Rearrangements

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma | Phase 2 | Status: WITHDRAWN